← Back to Search

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO Trial)

N/A
Recruiting
Led By Scott Palmer, MD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of study (3 years after last patient will be enrolled)
Awards & highlights
No Placebo-Only Group

Summary

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

Eligible Conditions
  • Pulmonary fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of study (3 years after last patient will be enrolled)
This trial's timeline: 3 weeks for screening, Varies for treatment, and end of study (3 years after last patient will be enrolled) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood samples for future research.
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
+2 more
Secondary study objectives
Data on center-specific practices on outcomes.
Data on management practices compared to existing guidelines.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,463 Previous Clinical Trials
2,978,905 Total Patients Enrolled
Boehringer IngelheimIndustry Sponsor
2,554 Previous Clinical Trials
15,894,295 Total Patients Enrolled
Scott Palmer, MDPrincipal InvestigatorDuke Clinical Research Institute, Duke University
3 Previous Clinical Trials
4,677 Total Patients Enrolled
~663 spots leftby Jan 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top